Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 11/20 | 0.59 |
| ▸ | PARP1 | P09874 | 6/20 | 0.59 |
| ▸ | SETD2 | Q9BYW2 | 4/20 | 0.42 |
| ▸ | NSD2 | O96028 | 1/20 | 0.42 |
| ▸ | APAF1 | O14727 | 1/20 | 0.40 |
| ▸ | CDC25B | P30305 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.40 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6645982 | 0.93 | TNKS (0.54) | TNKSPARP1SETD2NSD2APAF1 | |
| SCHEMBL6645174 | 0.86 | SETD2 (0.46) | TNKSPARP1SETD2NSD2APAF1 | |
| SCHEMBL6643880 | 0.86 | PARP1 (0.47) | TNKSPARP1SETD2NSD2APAF1 | |
| SCHEMBL6646307 | 0.86 | PARP1 (0.48) | TNKSPARP1APAF1CDC25BCASP3 | |
| SCHEMBL6647334 | 0.86 | TNKS (0.47) | TNKSPARP1SETD2NSD2APAF1 | |
| SCHEMBL6646697 | 0.86 | PARP1 (0.45) | TNKSPARP1SETD2NSD2APAF1 | |
| SCHEMBL6643181 | 0.85 | PARP1 (0.47) | TNKSPARP1APAF1CDC25BCASP3 | |
| SCHEMBL6643130 | 0.84 | TNKS (0.45) | TNKSPARP1SETD2NSD2APAF1 | |
| SCHEMBL6647905 | 0.84 | PARP1 (0.44) | TNKSPARP1SETD2NSD2APAF1 | |
| SCHEMBL6645853 | 0.84 | PARP1 (0.44) | TNKSPARP1SETD2NSD2APAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040176361-A1 | Fused heterocyclic compound and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2004-09-09 | — | — | US | claimed |
| EP-1396488-A1 | FUSED HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2004-03-10 | — | — | EP | claimed |
| US-20040176361-A1 | Fused heterocyclic compound and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2004-09-09 | — | — | US | disclosed |
| EP-1396488-A1 | FUSED HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2004-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176361-A1 | Fused heterocyclic compound and medicinal use thereof | PARP11, PARP1, CD38 | TNKS 121/4885PARP1 2/4885SETD2 1791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.